We are trading at basically 1 x revenue at this ridiculous level. Don't think about the small rally we have had in the past month or so. Think of how undervalued this play is with a 50mm market cap. We are about to go parabolic.
This stock is acting a lot differently now than it has in the past. When Goldman Sachs took their position, it became much less likely the shorts try to raid us with such a heavy hitter on board. Who in their right mind would short this stock anyway, with 18mm share O/S, 85% Complete response rate with zero side effects and used on over 40,000 patients worldwide? Slam dunk.
Lock it up for 6 months and come back when the buyers show up from J and J and Bristol Myers and Sanofi. It will get bought out unequivicolly right after FDA approval. The normal sell on news will not apply on FDA approval here. None of the bigs want a French company to put them out of business. If EDAP Alblatherm cures 85% of firstline PC patients, then how many refractory treatments will be left standing? Actually how many firstline treatments will be left standing? GLTA
I believe Goldman owns about 1.4mm shares of EDAP last time I checked. To define parabolic move:
In a "parabolic move", a stock starts going up. Buying interest increases dramatically, sending the stock into orbit. The stock is basically moving up in a straight line, giving the chart the look of a "parabola".